|
Exudative age-related macular degeneration
|
0.200 |
Biomarker
|
disease |
BEFREE |
This study aims to evaluate the role of complement factor H (CFH) in response to intravitreal ranibizumab (IVR) treatment, which is administered to patients with neovascular age-related macular degeneration (nAMD).
|
28471284 |
2018 |
|
Exudative age-related macular degeneration
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
C-reactive protein and complement factor H polymorphism interaction in advanced exudative age-related macular degeneration.
|
27778189 |
2017 |
|
Exudative age-related macular degeneration
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In the subgroup with genotype data, ARMS2 rs10490924 and CFH rs800292 were associated with nAMD.
|
28120909 |
2017 |
|
Exudative age-related macular degeneration
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Interaction analysis revealed the CFH SNP rs800292 has a highly significant interaction with the ANGPT2 SNP rs13269021 in nAMD and PCV in the combined analysis.
|
28192798 |
2017 |
|
Exudative age-related macular degeneration
|
0.200 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study of neovascular age-related macular degeneration in the Thai population.
|
28703135 |
2017 |
|
Exudative age-related macular degeneration
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
To compare the published results of studies on the genotype association of ARMS2/LOC387715 A69S, CFH Y402H, and CFH I62V in cases diagnosed as retinal angiomatous proliferation (RAP) versus neovascular age-related macular degeneration (AMD) or healthy controls.
|
28005184 |
2017 |
|
Exudative age-related macular degeneration
|
0.200 |
Biomarker
|
disease |
BEFREE |
In aqueous humor, significantly increased levels of Ba (P=0.002), and C3a (P=0.002) indicate local complement activation in nAMD patients and a trend for a concomitant upregulation of the complement regulators FH (P=0.02) and FI (P=0.04).ConclusionsOur findings provide strong evidence for a local complement dysregulation in nAMD patients.
|
28128795 |
2017 |
|
Exudative age-related macular degeneration
|
0.200 |
Biomarker
|
disease |
BEFREE |
CFH is implicated in nAMD patient treatment response to ranibizumab.
|
27362858 |
2016 |
|
Exudative age-related macular degeneration
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
CFH Y402H and VEGF Polymorphisms and Anti-VEGF Treatment Response in Exudative Age-Related Macular Degeneration.
|
27404493 |
2016 |
|
Exudative age-related macular degeneration
|
0.200 |
GeneticVariation
|
disease |
GWASCAT |
A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants.
|
26691988 |
2016 |
|
Exudative age-related macular degeneration
|
0.200 |
Biomarker
|
disease |
BEFREE |
Association of Smoking and CFH and ARMS2 Risk Variants With Younger Age at Onset of Neovascular Age-Related Macular Degeneration.
|
25695752 |
2015 |
|
Exudative age-related macular degeneration
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
To compare the functional and morphological response to the initial intravitreal (IVT) injection of bevacizumab in exudative age-related macular degeneration (AMD) patients with the complement factor H (CFH) gene polymorphism T1277C in the Brazilian population.
|
26439641 |
2015 |
|
Exudative age-related macular degeneration
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The purpose of this study is to investigate whether the Y402H polymorphism (rs1061170, a T-to-C transition at amino acid position 402) in the complement factor H (CFH) gene have a pharmacogenetics effect on the anti-vascular endothelial growth factor (VEGF) treatment for neovascular age-related macular degeneration (AMD).
|
26411831 |
2015 |
|
Exudative age-related macular degeneration
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
CFH Y402H and ARMS2 A69S Polymorphisms and Oral Supplementation with Docosahexaenoic Acid in Neovascular Age-Related Macular Degeneration Patients: The NAT2 Study.
|
26132079 |
2015 |
|
Exudative age-related macular degeneration
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, CFH rs1065489 did not show significant association with nAMD (P>0.01), but was strongly associated with PCV in Chinese patients (P<0.001).
|
25771815 |
2015 |
|
Exudative age-related macular degeneration
|
0.200 |
GeneticVariation
|
disease |
GWASCAT |
New loci and coding variants confer risk for age-related macular degeneration in East Asians.
|
25629512 |
2015 |
|
Exudative age-related macular degeneration
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
To investigate whether the polymorphism rs800292 (184G>A, rs800292" genes_norm="3075">I62V) in the complement factor H gene is associated with polypoidal choroidal vasculopathy (PCV) and the genetic difference between PCV and neovascular age-related macular degeneration (nAMD), in Asian populations.
|
24520367 |
2014 |
|
Exudative age-related macular degeneration
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The other 10 SNPs of CFH were significantly associated with the nAMD phenotype.
|
24692129 |
2014 |
|
Exudative age-related macular degeneration
|
0.200 |
Biomarker
|
disease |
BEFREE |
FPR1 interacts with CFH, HTRA1 and smoking in exudative age-related macular degeneration and polypoidal choroidal vasculopathy.
|
25277308 |
2014 |
|
Exudative age-related macular degeneration
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The variants in CFH, ARMS2 and near HTRA1 were strongly associated with both PCV (P < 10(-6), 10(-7) and 10(-7) respectively) and nAMD (P < 10(-6), 10(-16) and 10(-17) respectively).
|
23274582 |
2013 |
|
Exudative age-related macular degeneration
|
0.200 |
Biomarker
|
disease |
BEFREE |
To study the association of single-nucleotide polymorphisms of interleukin 8, vascular endothelial growth factor, erythropoietin, complement factor H, complement component C3, and LOC387715 genes with the response to bevacizumab treatment in exudative age-related macular degeneration.
|
23584701 |
2013 |
|
Exudative age-related macular degeneration
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Three previously reported associations of response to VEGF inhibition in nAMD involving single nucleotide polymorphisms (SNPs) at the CFH, FZD4, and HTRA1/ARMS2 loci were tested for replication.
|
24070809 |
2013 |
|
Exudative age-related macular degeneration
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Impact of loading phase, initial response and CFH genotype on the long-term outcome of treatment for neovascular age-related macular degeneration.
|
22848690 |
2012 |
|
Exudative age-related macular degeneration
|
0.200 |
Biomarker
|
disease |
BEFREE |
To determine whether there is an association between CFH, ARMS2, HTRA1, VEGF, SERPING1 or C3 genotypes and patient response to treatment with intravitreal bevacizumab for neovascular age-related macular degeneration (AMD).
|
22594510 |
2012 |
|
Exudative age-related macular degeneration
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
A69S and R38X ARMS2 and Y402H CFH gene polymorphisms as risk factors for neovascular age-related macular degeneration in Poland - a brief report.
|
22293892 |
2012 |